论文部分内容阅读
支气管哮喘(哮喘)是目前全世界最普遍的慢性病之一，80%的哮喘患者经过长期规范化治疗可达到临床控制，但仍有20%的哮喘患者表现为重症哮喘，其在第4级或第5级哮喘药物治疗下才能或甚至仍不能维持临床疗效，这给其自身和医疗系统带来巨大的负担。由于生物治疗直接针对哮喘发病的免疫机制，靶向哮喘发作的关键分子，生物治疗日益成为治疗重症哮喘的新星。本综述旨在通过讨论生物治疗在重症哮喘中的应用现状和前景，探讨生物治疗在重症哮喘临床治疗中的应用价值。“,”Bronchial asthma (asthma) is one of the most common chronic diseases in the world.80% of patients with asthma can achieve clinical control after long-term standardized treatment, while 20% of patients still have severe asthma.Patients with severe asthma can or even cann′t maintain clinical efficacy under the treatment of grade 4 or 5 asthma drugs, which brings a huge burden to themselves and the health care system.Since biotherapy directly targets the immune mechanism of asthma and the key molecules of asthma attack, biotherapy is becoming a new star in the treatment of severe asthma.The purpose of this review is to discuss the application status and prospect of biotherapy in the severe asthma setting, and to explore the application value of biotherapy in the clinical treatment of severe asthma.